Critical Care Research and Practice

Research Article

Immunocompromised Children with Severe Adenoviral Respiratory Infection

Table 2

Detailed descriptions of immunocompromised patients in analysis.


Case ID	Age (years)	Gender	PIM3 predicted mortality (percent)	Cause of immunocompromised state	Coinfections	MODS	ARDS	RRT	ECLS	Antiviral therapy	Case fatality

1	3	M	5.334	Hematopoetic stem cell transplant—allogeneic due to SCID, no GVHD; immunomodulators: mycophenolate mofetil, methylprednisolone, and cyclosporine	RSV, HRV/EV, and Alpha hemolytic Streptococcus in blood culture	Yes	No	Yes	No	Cidofovir, acyclovir	Yes

2	3	F	7.04	Neutropenia (ANC = 140/mm³) due to AML	HRV/EV	Yes	Yes	No	No	None	Yes

3	2	F	15.4	Hematopoetic stem cell transplant—liver, pancreas, and small bowel; immunomodulators: methylprednisolone	Enterobacter respiratory infection	Yes	Yes	Yes	Yes	Cidofovir, ganciclovir, investigational medication INV-CMX001 (liposomal cidofovir)	Yes

4	14	F	5.3	Hematopoetic stem cell transplant—allogeneic due to AML, possible GVHD; immunomodulators: mycophenolate mofetil and cyclosporine	None	Yes	Yes	Yes	No	Cidofovir, acyclovir, ganciclovir, and valacyclovir	Yes

5	18	F	5.6	Hematopoetic stem cell transplant—allogeneic due to Pre-B Cell ALL, no GVHD; immunomodulators: cyclosporine and methotrexate	HRV/EV	Yes	Yes	Yes	No	Cidofovir, acyclovir	Yes

6	2	F	5.5	Hematopoetic stem cell transplant—autologous due to relapsed retinoblastoma, no GVHD; immunomodulators: none	None	No	No	No	No	Acyclovir	No

7	2	M	1.3	Neutropenia (ANC 360/mm³) due to hemophagocytic lymphohistiocytosis	None	Yes	No	Yes	No	None	Yes

8	3	M	1.2	Neutropenia (ANC 0/mm³) due to Langerhans cell histiocytosis	None	No	No	No	No	Foscarnet, ganciclovir	No

9	1	F	0.14	Transient hypogammaglobulinemia of infancy	HRV/EV	No	No	No	No	None	No

10	5	M	1.1	Solid organ transplant—kidney; immunomodulators: prednisone, tacrolimus	HRV/EV	No	No	No	No	Valganciclovir	No

11	12	F	5.3	Hematopoetic stem cell transplant—allogeneic due to severe aplastic anemia, grade IV GVHD; immunomodulators: methylprednisolone, daclizumab, infliximab, and mycophenolate	None	Yes	No	Yes	No	Cidofovir, investigational medication INV-CMX001 (liposomal cidofovir)	Yes

12	4	F	6.5	Hematopoetic stem cell transplant—autologous due to neuroblastoma, no GVHD; immunomodulators: none	None	Yes	Yes	No	No	Cidofovir	Yes

13	11	M	5.4	Hematopoetic stem cell transplant—allogeneic due to AML, GVHD; immunomodulators: mycophenolate mofetil, and prednisolone	None	Yes	Yes	Yes	No	Cidofovir, ribavirin	Yes

14	4	F	5.8	Hematopoetic stem cell transplant—allogeneic due to SCID variant, no GVHD; immunomodulators: cyclosporine and mycophenolate mofetil	None	Yes	No	No	No	Cidofovir, foscarnet, and cytogam	Yes

15	3	F	5.4	Hematopoetic stem cell transplant—allogeneic for Sickle Cell Disease, GVHD grade IV; immunomodulators: Methylprednisolone, Extracorporeal photopheresis, tacrolimus, cyclosporine, infliximab, rituximab, and mycophenolate mofetil	None	No	No	No	No	Cidofovir, brincidofovir, and acyclovir	Yes

16	<1	M	1.1	DiGeorge Syndrome	None	No	No	No	No	None	No

17	13	F	1.1	Solid organ transplant—kidney; immunomodulators: prednisone, cellcept, and rapamune	None	Yes	Yes	No	No	Cidofovir	No

18	17	M	1.2	Wiscott-Aldrich Syndrome	HRV/EV	No	No	No	No	None	No

19	8	M	1	Common variable immune deficiency	HRV/EV, Alpha hemolytic Streptococcus from BAL sample	No	No	No	No	None	No

AML: acute myeloid leukemia; ANC: absolute neutrophil count; ALL: acute lymphoblastic leukemia; ARDS: acute respiratory distress syndrome; BAL: bronchoalveolar lavage; ECLS: extracorporeal life support; GVHD: graft-versus-host disease; HRV/EV: human rhino-/enterovirus; MODS: multiple organ dysfunction syndrome; RRT: renal replacement therapy; RSV: respiratory syncytial virus; SCID: severe combined immunodeficiency.